Better Health for All

Lisata Therapeutics is a clinical-stage pharmaceutical company entirely focused on developing certepetide, a cyclic peptide designed to enhance anti-cancer treatments for various solid tumors, including pancreatic, colon, and appendiceal cancers.

Clinical trials show significant efficacy, with preliminary findings from one trial reporting a 60% overall response rate and 100% disease control rate in locally advanced pancreatic ductal adenocarcinoma. Other trials demonstrated improvements in median overall survival rates by 55% (from 8.5 to 13.2 months) in Australia and 31% (from 8.5 to 11.1 months) in China for metastatic pancreatic ductal adenocarcinoma. The company has received Fast Track, Rare Pediatric Disease, and Orphan Drug designations from the FDA and EMA. Certepetide has been well tolerated in clinical trials at recommended doses and exhibited low systemic toxicity in preclinical models. However, specific quantitative adverse event rates are not provided. The company currently has no revenue. Projected pricing for certepetide in the US is $120,000 per patient per year, which is 83% of the average price of comparable oncology drugs ($144,000 p.a.). This pricing is significantly higher than estimated production costs, which are not disclosed. The company holds a portfolio of patents related to its CendR Platform® technology and certepetide. While the company is conducting trials globally, there is no specific evidence of programs to ensure equitable access for low-income or marginalized populations. The company acknowledges various risks, including development, regulatory, competition, and financial risks, but specific details on risk transparency in marketing or disclosures are not provided. Many of its clinical trials are designed as double-blind, placebo-controlled, and randomized, indicating adherence to high ethical standards.

No War, No Weapons

The provided articles do not contain any specific information or quantitative data points related to Lisata Therapeutics, Inc. (LSTA.US) concerning its association with arms manufacturing, military contracts, or conflict facilitation.

All articles explicitly state that they do not contain data directly relevant to LSTA.US or the 'No War, No Weapons' value, focusing instead on general US government contracting and the broader defense industry.

Planet-Friendly Business

No specific, concrete data points were found in the provided articles for Lisata Therapeutics, Inc. (LSTA.US) regarding any of the Planet-Friendly Business KPIs. The articles discuss general industry trends, a project to develop a framework for assessing clinical trial environmental impact,

and AstraZeneca's sustainability efforts, but do not provide any environmental performance data for LSTA.US itself.

Safe & Smart Tech

Lisata Therapeutics states it takes commercially reasonable steps to protect personal data and has no documented data breaches or unauthorized data use incidents. Users can choose not to provide personal data and can contact the company to update or correct their data, but the privacy policy does not explicitly mention data deletion options or comprehensive privacy controls, indicating basic data control with significant limitations.

The company's policy does not explicitly mention data minimization practices beyond providing third-party companies only the information needed for specific functions, which aligns with good data minimization practices. Lisata may disclose personal data if required by law, but the policy does not detail a comprehensive compliance program or proactive approach to regulations. The company does not knowingly collect personal data from children under 13. Lisata's CEO advocated for upholding FDA standards for AI safety and efficacy in drug development, and the company partners with GATC Health, which uses an AI platform with >85% precision in predicting safety and efficacy. However, there is no evidence of Lisata's internal AI ethics governance, audit practices, cybersecurity investment, encryption implementation, security training, testing coverage, vulnerability management, or bug bounty programs.